Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGM
$6.52
-0.04 (-0.61%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-35.6M · quality 65.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$429M
P/E
N/A
•EV/EBITDA
N/A
•ROE
223.5%
↑Gross Margin
66.3%
↑Debt/Equity
-6.71
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-17.1%
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $297.2M · net income $-51.6M · FCF $-50.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $297.2M | $297.2M | $266.3M | $202.1M | $148.6M | $99.7M | $56.5M | $34.9M | $0.00 | — |
| Net Income | $-51.6M | $-51.6M | $-50.4M | $-61.7M | $-74.4M | $-46.8M | $-163.0M | $-90.0M | $-46.9M | $-4.5M |
| EBITDA | $-22.5M | $-22.5M | $-25.0M | $-41.8M | $-60.7M | $-38.8M | $-146.0M | $-94.8M | $-46.1M | $-11.5M |
| EPS | -0.80 | -0.80 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | — | — | — |
| Gross Margin | 66.3% | 66.3% | 68.5% | 68.1% | 60.4% | — | — | 77.1% | — | — |
| Operating Margin | -12.7% | -12.7% | -10.2% | -22.3% | -40.1% | -44.6% | -270.7% | -283.3% | — | — |
| Net Margin | -17.4% | -17.4% | -18.9% | -30.5% | -50.1% | -47.0% | -288.3% | -257.8% | — | — |
| Balance Sheet | ||||||||||
| Debt/Equity | -6.71 | -6.71 | 23.54 | -6.12 | 4.02 | 0.87 | — | 0.93 | 0.00 | — |
| Current Ratio | 2.04 | 2.04 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-50.7M | $-50.7M | $-22.8M | $-35.6M | $-87.9M | $-33.8M | $-58.7M | $-93.7M | $-25.7M | $-13.2M |
| Returns | ||||||||||
| ROE | 223.5% | 223.5% | -913.1% | 298.2% | -402.2% | -57.2% | 223.4% | -113.3% | -55.5% | 5.9% |
| Valuation | ||||||||||
| P/B | — | — | 129.97 | — | 23.67 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | 11.6% | 11.6% | 31.8% | 36.0% | — | 76.3% | 61.9% | — | — | — |
| EPS Growth | 1.2% | 1.2% | 25.0% | 18.8% | — | 80.5% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.81 → -0.80
Residual
-29.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.